local_hospital

University Hospital Maastricht

Address
lock Available on a paid plan

Oncology and Respiratory Research

At University Hospital Maastricht, clinical trials in neoplasms and respiratory tract diseases focus on cancers such as small-cell lung cancer, non-small cell lung cancer, head and neck cancer, and lymphoma. These studies are designed to test new treatment options, compare them with current standards, and improve outcomes for people with advanced or difficult-to-treat disease.

  • Evaluating new immunotherapy and targeted treatment approaches for lung cancer
  • Comparing treatment strategies in head and neck cancer and lymphoma
  • Studying better ways to extend survival and control disease progression

The research also includes personalized approaches for specific tumor features, reflecting a strong interest in matching treatment to the biology of each cancer.

Women’s Health and Gynecologic Cancer

The site’s Gynaecology department is involved in trials for cervical cancer and endometrial cancer, with a clear focus on refining treatment while preserving quality of life. These studies explore whether newer therapies can improve cancer control and, in selected patients, support fertility-sparing care.

  • Testing treatment options for cervical cancer and mismatch-repair deficient endometrial cancer
  • Assessing whether treatment can be effective while reducing long-term impact on fertility
  • Improving outcomes after surgery in gynecologic oncology

This area of research combines cancer treatment with a patient-centered approach, especially for women who may benefit from less invasive life planning after therapy.

Digestive System and Neuroendocrine Research

Trials in digestive system diseases at University Hospital Maastricht include studies in colon cancer, chronic pancreatitis, and neuroendocrine tumours. The goal is to improve treatment effectiveness, relieve symptoms, and identify better ways to track disease behavior.

  • Evaluating new treatment approaches for resectable colon cancer
  • Studying pain relief in chronic pancreatitis
  • Assessing treatment continuation strategies in neuroendocrine tumours

This research reflects both cancer-focused care and efforts to improve symptom management in long-term digestive conditions.

Cardiovascular and Thrombotic Studies

The cardiovascular diseases portfolio includes research on subclinical heart failure and proximal deep vein thrombosis. These trials aim to improve early cardiac remodeling, support better heart function, and evaluate whether new clot-busting treatment options can be both effective and safe.

  • Testing strategies to reverse early changes in heart failure
  • Assessing new treatment options for deep vein thrombosis
  • Measuring safety and clinical benefit in vascular disease care

The research combines prevention-oriented cardiology with treatment development for patients at risk of serious vascular complications.

Immune, Infectious, and Transplant-Related Research

Clinical trials in immune system diseases and virus diseases address impaired immunity, kidney transplantation, and COVID-19. These studies are focused on improving immune responses, strengthening vaccine effectiveness, and supporting safer care for transplant recipients and other vulnerable groups.

  • Studying how to improve COVID-19 vaccination responses in kidney transplant patients
  • Exploring immune function in people with impaired immunity
  • Supporting safer treatment choices for patients with complex immune needs

This area highlights practical research aimed at reducing infection-related risk while protecting long-term health.

Ear, Skin, and Diagnostic Research

The site also conducts studies in otorhinolaryngologic diseases, skin and connective tissue diseases, and analytical, diagnostic and therapeutic techniques. Research includes Menière's disease, actinic keratosis, and diagnostic work for carcinoma of unknown primary.

  • Testing symptom relief strategies for Menière's disease
  • Evaluating treatment for actinic keratosis on the face or scalp
  • Improving diagnostic methods to identify the origin of unknown primary cancer

These trials combine everyday clinical care with efforts to improve diagnosis and local disease control across several specialty areas.

Site Overview

assignment
269
connected trials
corporate_fare
110
sponsors
science
381
IMPs

Activity Indicator

Last 6 months

20
Trials started
-33% vs previous period.
30
Trials started 6–12 months ago
269
Total trials linked
Highly Active
trending_downDeclining-33%
3
4
8
1
4
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 29 therapeutic areas and 15 of 381 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 365 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
159
Sponsors (total)
110
Active sponsors
72

Sponsor Network

Top 72 by active trials.

lock +71 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +43 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
269
Outperforms 97% of sites
public
Therapeutic diversity
29areas
Outperforms 97% of sites
groups
Sponsor diversity
110sponsors
Outperforms 98% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Hospital Maastricht

lock Showing 1 of 269 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)Myokardia Inc.Phase IIINot RecruitingSep 2019Jan 2026

IMP list

lock Showing 1 of 381 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab25Unknown2015-07-162026-07-08

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.